Transforming biomanufacturing economics
Embedded Files
THE PROBLEM
In industrial biotech, the story has played out again and again: scientists develop microbes that turn low-cost raw materials—even waste—into higher-value products more purely, humanely, and sustainably. Startups launch and demonstrate success at the bench, pilot, or even industrial scale. Yet most efforts to commercialize these ideas fail to deliver on that promise.
The problem? They simply can’t produce profitably, despite raising hundreds of millions.
The underlying issue: Industrial biotech relies on a decades-old platform that is now a generation behind the science.
DEEP DIVE
Technoeconomic analysis (TEA) highlights:
Core process equipment is not the main cost driver.
Balance of Plant (BOP) outspends equipment by 250~600%, and can’t be outsourced.
Up to 90% of expenses go toward production readiness—not production itself
Equipment
Auxillary System
High Graded Facility
Software
THE APPROACH
Unblok Bio develops fit-for-purpose biomanufacturing platform to unlock commercial viability of industrial biotech products.
Transactional operations: ultra-high equipment utilization, reducing equipment number and complexity
Plug-n-play modular design, lowering balance of plant (BOP) cost and reducing project timeline.
Aseptic operation in non-graded facility.
Native support for intensified process (batch refeed, continuous, and perfusion).
Non-hierachical operation system
Radical innovation to minimize raw materials and consumables
IMPACT
Unblok Bio Value Propostions
Unblok Bio Value Propostions
Deployment: CAPEX saving by 70–90% and cut project timeline by 60~80%
Operational Efficiency: OPEX saving by 50–80%
Life Cycle Impact: Capital efficiency throughout R&D, pilot&industrial demo, and full scaling
THE OPPORTUNITY
Unblok Bio exists to turn unfulfilled promises into reality
Synthetic Biology
Synthetic Biology
Biology is magic. It's time to pair it with bold engineering.
Biomaterials
Biomaterials
Close to the tipping point. Just a small push to move from niche to mainstream.
Cellular Agriculture
Cellular Agriculture
The food revolution started. The profitability revolution is next.
Will IT WORK?
Technical and Economic Validation
While the integrated platform is novel, its underlying technical principles and key elements have been validated in distinct operational contexts.
Techno-economic analysis confirms significant CAPEX and OPEX savings
PARTNER WITH UNBLOK
Unblok Bio partners with industrial biotech companies to advance their goals across every stage of growth.
Unblok Bio partners with industrial biotech companies to advance their goals across every stage of growth.
For early-stage partner: TEA/LCA tools guide right-priority, de-risked, cost-effective process development from day one.
For mid-stage partner: Plug-n-play, scalable equipment for fast bench-to-pilot transition at much lower capex/opex.
Scale-up to industrial: End-to-end platform strategy and equipment, and commissioning support
Capacity expansion: Hyperscaling-ready platform for a paradigm shift in commodity biomanufacturing.
Operational Boundaries: Unblok Bio operates strictly in the B2B middle value chain through platform technology. To prevent conflicts of interest, we deliberately choose not to develop proprietary strains, cell lines, or consumer retail products.
GET IN TOUCH
Zheng Huang, Ph.D.
Founder & CEO
Unblok Bioprocess, Inc.
zheng@unblokbio.com
Page updated
Report abuse